What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Erenumab 140 mg demonstrated a moderate benefit in reducing monthly migraine days compared to best supportive care, with a statistically significant reduction of 4.1 days more than placebo in chronic migraine. However, the evidence for the 70 mg dosage was less compelling, showing only a modest reduction of 2.5 days, and the overall effectiveness in episodic migraine was uncertain. Thus, while there is clear evidence of efficacy, the variability in results and the lack of direct comparisons with botulinum toxin type A limit the rating to A.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for erenumab are within the acceptable range typically considered by NICE, with ICERs around £20,000 per QALY gained. The committee concluded that erenumab is cost-effective for chronic migraine and episodic migraine after three preventive treatments have failed, indicating a strong economic value proposition.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that migraine significantly impacts health-related quality of life, and erenumab is associated with improvements in quality of life metrics. The patient experts highlighted the debilitating nature of migraines and the need for effective treatments that improve daily functioning. While the exact HRQoL data from the trials were not robustly detailed, the overall context supports a moderate improvement in quality of life.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Erenumab has a favorable safety profile, with low rates of serious adverse events and tolerability comparable to placebo. The committee noted that most adverse events were of low to moderate severity, suggesting that erenumab is well tolerated among the studied populations.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparisons were made against best supportive care and placebo, which are appropriate for the context. However, the lack of direct evidence comparing erenumab with botulinum toxin type A introduces some limitations, as the indirect comparisons showed uncertain results.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a relevant patient population of individuals who had failed at least three previous treatments, which reflects the intended real-world use of erenumab. However, concerns were raised about the exclusion of certain subgroups, which may limit generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Erenumab can be integrated into existing care pathways with manageable adjustments, as it is a self-injectable treatment that can be administered at home after initial training. This aligns well with current clinical practices for migraine management.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model captures all relevant costs associated with erenumab, including administration and monitoring. The committee noted that the resource implications are manageable and align with the expected use of the treatment.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes multiple randomized controlled trials, although there are some methodological concerns and limitations regarding the generalizability of the results. The overall quality of evidence is acceptable, supporting the conclusions drawn.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term effectiveness of erenumab and its comparative efficacy against botulinum toxin type A. The committee acknowledged these uncertainties, which could impact decision-making and the broader implications for healthcare.
